Sabrina Serani is a senior editor for Targeted Oncology.
FDA’s ODAC Confronts Issues With Accelerated Approval Program
November 16th 2023The FDA’s Oncologic Drugs Advisory Committee discussed delays that can occur when drugs are granted accelerated approval, and the post-approval confirmatory trials of pralatrexate and belinostat for peripheral T-cell lymphoma.
PDS0101, PDS0301, and Bintrafusp Alfa Enhances Survival in HPV+ Cancers
November 10th 2023The combination of and investigational immune checkpoint inhibitor, immunotherapy, and antibody-drug conjugate showed improvements in overall survival in patients with a variety of human papillomavirus-positive cancers.
Do Race and Ethnicity Affect Response to CAR T-Cell Therapy?
October 27th 2023While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC
October 20th 2023Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.